### This week in therapeutics

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target/marker/pathway</th>
<th>Summary</th>
<th>Licensing status</th>
<th>Publication and contact information</th>
</tr>
</thead>
</table>
| Cancer              | *Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K)*                  | Studies in mice and patient samples suggest an anti-KIR3DL2 antibody could help treat the mycosis fungoides and Sézary syndrome subtypes of CTCL, which overexpress KIR3DL2. In two mouse xenograft models of KIR3DL2+ CTCL, the anti-KIR3DL2 mAb IPH4102 decreased tumor growth and increased survival compared with an inactive control mAb. In peripheral blood monocytes from patients with Sézary syndrome, IPH4102 increased tumor cell death compared with control without affecting the viability of NK cells. Innate Pharma S.A. plans to start a Phase I trial of IPH4102 in CTCL next year. | Patented by Innate Pharma; available for licensing and partnering | Marie-Cardine, A. et al. Cancer Res.; published online Nov. 1, 2014; doi:10.1158/0008-5472.CAN-14-1456  
Contact: Hélène Sicard, Innate Pharma S.A., Marseille, France  
e-mail: helene.sicard@innate-pharma.fr  
Contact: Anne Marie-Cardine, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France  
e-mail: anne.marie-cardine@inserm.fr |

SciBX 7(46); doi:10.1038/scibx.2014.1348  
Published online Dec. 4, 2014